Related Experiment Video
Updated: Jun 25, 2025
07:32
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
1.3K
Biomarker in Hepatocellular Carcinoma
Pooja Basthi Mohan1, Rajiv Lochan1,2, Shiran Shetty1
1Department of Gastroenterology and Hepatology, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, 576104 Karnataka India.
Indian Journal of Surgical Oncology
|May 31, 2024
Summary
Hepatocellular carcinoma (HCC), a prevalent cancer, often presents late. Novel biomarkers offer hope for earlier diagnosis and improved treatment, enhancing patient survival and reducing healthcare burdens.
Area of Science:
- Oncology
- Biomarker Discovery
- Hepatocellular Carcinoma Research
Background:
- Liver cancer, particularly HCC, poses a significant global health and economic challenge.
- Late-stage diagnosis limits treatment options for HCC, emphasizing the need for early detection.
- Current biomarkers like alpha-fetoproteins have limitations for early HCC diagnosis and staging.
Purpose of the Study:
- To review novel biomarkers for early hepatocellular carcinoma (HCC) diagnosis.
- To highlight emerging technologies and areas revolutionizing cancer management.
- To identify biomarkers that improve patient outcomes and reduce the burden of care.
Main Methods:
- Comprehensive literature review of recent research on novel HCC biomarkers.
- Analysis of preliminary studies validating biomarker efficacy.
- Synthesis of findings on emerging diagnostic and therapeutic strategies.
Main Results:
- Identification of multiple novel biomarkers showing promise in preliminary trials for HCC.
- Validation of these biomarkers in diverse research settings.
- Emerging technologies are transforming the landscape of cancer diagnosis and management.
Conclusions:
- Novel biomarkers are crucial for overcoming the limitations of current HCC diagnostic tools.
- Early detection through advanced biomarkers can lead to more effective, targeted therapies.
- Continued research and technological advancements are vital for improving HCC patient survival and quality of life.
